Imperial College London, London, UK.
Neurobiology Research Unit, Rigshospitalet, Denmark.
J Psychopharmacol. 2019 Sep;33(9):1068-1075. doi: 10.1177/0269881119827891. Epub 2019 Feb 28.
Recent studies have suggested therapeutic benefits of psychedelics for a variety of mental health conditions. The understanding of how single psychedelic administrations can induce long-lasting effects are, in large, still lacking. However, recent studies in both healthy and clinical populations suggest a role for personality changes.
To test support for some of these plausible mechanisms we evaluated (cross-sectional) associations between recreational use of psychedelics and 3,4-methylene-dioxymethamphetamine (MDMA) and (a) personality measures and (b) key markers of cerebral serotonergic signalling (serotonin transporter and serotonin-2A-receptor binding).
In 10 psychedelic-preferring recreational users, 14 MDMA-preferring users and 21 non-using controls, personality was assessed using the 'big five' instrument Revised NEO Personality Inventory (NEO-PI-R). Frontal serotonin transporter and serotonin-2A-receptor binding potentials were quantified using [C]DASB and [F]altanserin positron emission tomography, respectively.
Of the five NEO-PI-R traits, only openness to experience scores differed between the three groups; psychedelic-preferring recreational users showing higher openness to experience scores when compared with both MDMA-preferring users and controls. Openness to experience scores were positively associated with lifetime number of psychedelic exposures, and among all MDMA-preferring user/psychedelic-preferring recreational user individuals, frontal serotonin transporter binding - but not frontal serotonin-2A-receptor binding - was positively associated with openness to experience.
Our findings from this cross-sectional study support increasing evidence of a positive association between psychedelic experiences and openness to experience, and (a) expands this to the context of 'recreational' psychedelics use, and (b) links serotonergic neurotransmission to openness to experience. A modulation of personality induced by psychedelic experiences may have important therapeutic implications via its impact on peoples' value systems, cognitive flexibility, and individual and social behaviour.
最近的研究表明,迷幻剂对多种心理健康状况具有治疗益处。人们对单一迷幻剂给药如何产生持久影响的理解在很大程度上仍然缺乏。然而,最近在健康人群和临床人群中的研究表明,人格变化起着作用。
为了验证其中一些合理机制,我们评估了娱乐性使用迷幻剂和 3,4-亚甲二氧基甲基苯丙胺(MDMA)与(a)人格测量和(b)大脑 5-羟色胺能信号关键标志物(5-羟色胺转运体和 5-羟色胺 2A 受体结合)之间的(横断面)关联。
在 10 名喜欢使用迷幻剂的娱乐性使用者、14 名喜欢使用 MDMA 的使用者和 21 名非使用者对照者中,使用“大五”工具修订版 NEO 人格量表(NEO-PI-R)评估人格。使用 [C]DASB 和 [F]altanserin 正电子发射断层扫描分别量化额皮质 5-羟色胺转运体和 5-羟色胺 2A 受体结合潜能。
在五个 NEO-PI-R 特质中,只有开放性特质得分在三组之间存在差异;与 MDMA 偏好使用者和对照组相比,喜欢使用迷幻剂的娱乐性使用者表现出更高的开放性特质得分。开放性特质得分与一生中使用迷幻剂的次数呈正相关,并且在所有 MDMA 偏好使用者/喜欢使用迷幻剂的娱乐性使用者中,额皮质 5-羟色胺转运体结合-而不是额皮质 5-羟色胺 2A 受体结合-与开放性特质呈正相关。
我们这项横断面研究的结果支持越来越多的证据表明迷幻剂体验与开放性特质之间存在正相关,(a)将这一发现扩展到“娱乐性”迷幻剂使用的背景下,(b)将 5-羟色胺能神经传递与开放性特质联系起来。迷幻剂体验引起的人格改变可能通过其对人们的价值观、认知灵活性以及个人和社会行为的影响而具有重要的治疗意义。